Theriva Biologics
TOVX
34 hedge funds and large institutions have $3.32M invested in Theriva Biologics in 2021 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 2 reducing their positions, and 0 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 2
26% more funds holding
Funds holding: 27 → 34 (+7)
0% more ownership
Funds ownership: 0.02% → 0.02% (+0%)
15% less capital invested
Capital invested by funds: $3.91M → $3.32M (-$591K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$137K |
| 2 |
Two Sigma Investments
New York
|
+$95.2K |
| 3 |
Two Sigma Advisers
New York
|
+$47K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$26.1K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$16.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$28.7K |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
-$498 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Creative Planning
Overland Park,
Kansas
| $5K | – | – | – |
|
|
SWP
27
Stratos Wealth Partners
Beachwood,
Ohio
| $5K | – | – | – |
|
|
IA
28
IFP Advisors
Tampa,
Florida
| $3K | – | – | – |
|
29
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$124 | +1 | New |
|
30
Bank of America
Charlotte,
North Carolina
| – | +$373 | +3 | New |
|
TOVX Hedge Fund Activity: Q3 2021 in Review
34 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q3 2021, worth a combined $3.32M — down 15% from $3.91M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new TOVX positions and 0 closed out — a net gain of 7 holders — while 8 added to existing stakes and 2 trimmed.
The largest buyer was GSA Capital Partners, opening a new position worth an estimated $137K. The largest seller was Virtu Financial, cutting an estimated $28.7K.
- 34 institutional investors held Theriva Biologics (TOVX) as of Q3 2021, up from 27 in Q2 2021.
- Funds reported $3.32M of Theriva Biologics stock for Q3 2021, down 15% quarter-over-quarter.
- 7 funds opened new Theriva Biologics positions in Q3 2021 and 0 closed out, a net change of +7 holders.
- The largest Theriva Biologics buyer in Q3 2021 was GSA Capital Partners, an estimated $137K added.
- The largest Theriva Biologics seller in Q3 2021 was Virtu Financial, an estimated $28.7K sold.
Based on aggregated 13F filings for Q3 2021.